MOSCOW, October 16. /TASS/. The Russian Direct Investment Fund (RDIF) sees the interest of many countries exactly in the nasal form of the Sputnik V coronavirus vaccine, chief executive of RDIF Kirill Dmitriev said in a documentary showed on the Rossiya-24 TV Channel.

"We see the strongest interest in the intranasal form. It can be used together with the conventional form of the vaccine but as new strains appear, we believe the nasal form has the promising future, and we see the very strong interest exactly in the intranasal form from various countries. Clinical trials also showed the highest efficiency of the intranasal vaccine," Dmitriev said.

Dmitriev stressed that he had used the intranasal vaccine himself. "It is indeed the form having very good protection against virus penetration into the organism and is a kind of a ‘gentle’ vaccine form, he noted. "The nasal form is the advantage of the adenovirus vector present in the Sputnik vaccine: the chief executive added.

In August 2020, Russia became the world’s first country that registered the coronavirus vaccine named Sputnik V. The vaccine is registered in more than 70 countries of the world to date.